ResMed (WBO:RMD) Loans Receivable : €0 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is ResMed Loans Receivable?

ResMed's Loans Receivable for the quarter that ended in Dec. 2023 was €0 Mil.

ResMed Loans Receivable Historical Data

The historical data trend for ResMed's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Loans Receivable Chart

ResMed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Loans Receivable

Get a 7-Day Free Trial

ResMed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

ResMed Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

ResMed Loans Receivable Related Terms

Thank you for viewing the detailed overview of ResMed's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed (WBO:RMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (WBO:RMD) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMEA:Germany R1MD34:Brazil RMD:Australia

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.